New vaccine aims to tackle two viruses behind hand, foot, and mouth disease

NCT ID NCT06063057

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tested a new vaccine designed to protect against two viruses (EV71 and CA16) that cause hand, foot, and mouth disease and herpangina. The study involved 744 healthy adults and children, including kids as young as 6 months. Researchers checked the vaccine's safety and how well it triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

What this could lead to

If successful, this vaccine could help prevent hand, foot, and mouth disease and herpangina caused by two common viruses (EV71 and CA16).

What could go wrong

This is an early-phase trial (Phase I/II) focused on safety and immune response, not yet proven to prevent disease. Results may not lead to a licensed vaccine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAND, FOOT AND MOUTH DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hand, foot and mouth disease prevention target herpangina prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dayao County Center for Disease Control and Prevention

    Chuxiong, Yunnan, China